Drug Profile
HIF-1 alpha gene therapy - Sanofi
Alternative Names: Ad2/HIF-1 alpha; Ad2/HIF-1a; Ad2/HIF-1α/VP16; Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16; Cardiovascular disease gene therapy - SanofiLatest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Sanofi
- Class Gene therapies; Peripheral vasodilators
- Mechanism of Action Angiogenesis inducing agents; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Intermittent claudication; Peripheral arterial disorders
- Discontinued Ischaemic heart disorders
Most Recent Events
- 31 Mar 2012 No development reported - Phase-II for Intermittent claudication in European Union (IM)
- 31 Mar 2012 No development reported - Phase-II for Intermittent claudication in USA (IM)
- 31 Mar 2012 No development reported - Phase-II for Peripheral arterial disorders in European Union (IM)